{
    "clinical_study": {
        "@rank": "127660", 
        "arm_group": [
            {
                "arm_group_label": "CD07805/47 gel Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }, 
            {
                "arm_group_label": "CD07805/47 gel", 
                "arm_group_type": "Experimental", 
                "description": "Intervention: Drug: CD07805/47 gel"
            }
        ], 
        "brief_summary": {
            "textblock": "Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema\n      associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once\n      daily is more efficacious than vehicle and provides an acceptable safety profile in the\n      treatment of facial erythema associated with rosacea"
        }, 
        "brief_title": "Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Rosacea", 
        "condition_browse": {
            "mesh_term": "Rosacea"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          1. Male or female who is at least 18 years of age or older.\n\n          2. A clinical diagnosis of facial rosacea.\n\n          3. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at\n             Screening and at Baseline/Day 1 (prior to the study drug application).\n\n          4. A Patient Self Assessment (PSA) score of greater than or equal to 3 at Screening and\n             at Baseline/Day 1 (prior to the study drug application).\n\n        Key Exclusion Criteria:\n\n          1. More than 20 facial inflammatory lesions of rosacea\n\n          2. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated\n             rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses\n             that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial\n             keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic\n             telangiectasia.\n\n          3. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates,\n             sedatives, systemic anesthetics, or alpha agonists.\n\n          4. Less than 3 months stable dose treatment with tricyclic anti depressants, cardiac\n             glycosides, beta blockers or other antihypertensive agents.\n\n          5. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic\n             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal\n             or hepatic impairment, scleroderma, Sj\u00f6gren's syndrome, or depression."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "114", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01789775", 
            "org_study_id": "RD.03.SPR.40174"
        }, 
        "intervention": [
            {
                "arm_group_label": "CD07805/47 gel Placebo", 
                "intervention_name": "Drug: CD07805/47 gel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CD07805/47 gel", 
                "intervention_name": "CD07805/47 gel Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 12, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chelyabinsk", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint-Petersburg", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Galderma Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "France", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "2", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Sweden: Medical Products Agency", 
                "Sweden: Regional Ethical Review Board", 
                "Russia: Pharmacological Committee, Ministry of Health", 
                "Russia: Ethics Committee"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).", 
            "measure": "Composite Success Assessment (CEA) and Patient Self Assessment(PSA).", 
            "safety_issue": "No", 
            "time_frame": "Day 29"
        }, 
        "removed_countries": {
            "country": "Sweden"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01789775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "30 Minutes Effect is defined as 1 grade improvement on CEA and PSA at 30 minutes.", 
            "measure": "Composite Success Assessment (CEA) and Patient Self Assessment(PSA).", 
            "safety_issue": "No", 
            "time_frame": "D1"
        }, 
        "source": "Galderma R&D", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Galderma R&D", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}